PH12012501402A1 - Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease - Google Patents
Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart diseaseInfo
- Publication number
- PH12012501402A1 PH12012501402A1 PH1/2012/501402A PH12012501402A PH12012501402A1 PH 12012501402 A1 PH12012501402 A1 PH 12012501402A1 PH 12012501402 A PH12012501402 A PH 12012501402A PH 12012501402 A1 PH12012501402 A1 PH 12012501402A1
- Authority
- PH
- Philippines
- Prior art keywords
- aqueous solution
- autoimmune
- quinuclidinones
- heart disease
- treatment
- Prior art date
Links
- 239000007864 aqueous solution Substances 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- ZKMZPXWMMSBLNO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one Chemical class C1CC2C(=O)CN1CC2 ZKMZPXWMMSBLNO-UHFFFAOYSA-N 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29696410P | 2010-01-21 | 2010-01-21 | |
| EP10151326 | 2010-01-21 | ||
| PCT/EP2011/050854 WO2011089234A2 (en) | 2010-01-21 | 2011-01-21 | Method and composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12012501402A1 true PH12012501402A1 (en) | 2016-07-27 |
Family
ID=42212171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2012/501402A PH12012501402A1 (en) | 2010-01-21 | 2011-01-21 | Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9061016B2 (enExample) |
| EP (1) | EP2525796B1 (enExample) |
| JP (2) | JP5845193B2 (enExample) |
| KR (1) | KR101727085B1 (enExample) |
| CN (2) | CN106963759B (enExample) |
| AU (1) | AU2011208681B2 (enExample) |
| BR (1) | BR112012017994B8 (enExample) |
| CA (1) | CA2786824C (enExample) |
| CY (1) | CY1117659T1 (enExample) |
| DK (1) | DK2525796T3 (enExample) |
| ES (1) | ES2578513T3 (enExample) |
| HU (1) | HUE028285T2 (enExample) |
| IL (1) | IL220318A (enExample) |
| IN (1) | IN2012DN05192A (enExample) |
| PH (1) | PH12012501402A1 (enExample) |
| PL (1) | PL2525796T3 (enExample) |
| PT (1) | PT2525796T (enExample) |
| RU (1) | RU2571566C2 (enExample) |
| SG (1) | SG182537A1 (enExample) |
| SM (1) | SMT201600189B (enExample) |
| WO (1) | WO2011089234A2 (enExample) |
| ZA (1) | ZA201204424B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9061016B2 (en) * | 2010-01-21 | 2015-06-23 | Aprea Ab | Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease |
| CN104860994A (zh) * | 2014-02-20 | 2015-08-26 | 中国药科大学 | 3-奎宁环酮类含磷化合物的制备及其医药用途 |
| CN109280056A (zh) * | 2017-07-21 | 2019-01-29 | 上海时莱生物技术有限公司 | 手性3-奎宁环酮类化合物、制备方法及用途 |
| EP3762035A4 (en) * | 2018-03-09 | 2022-03-02 | Texas Tech University System | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER IN ALT |
| US20220087987A1 (en) * | 2018-12-27 | 2022-03-24 | National Cancer Center | A method for treating swi/snf complex-deficient cancers comprising glutathione (gsh) metabolic pathway inhibitor |
| CA3154120A1 (en) | 2019-09-18 | 2021-03-25 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein |
| CN116034107A (zh) * | 2020-02-09 | 2023-04-28 | 新波制药有限公司 | 用作抗癌剂的奎宁环酮类似物 |
| CN111257458B (zh) * | 2020-02-20 | 2022-07-22 | 北京鑫开元医药科技有限公司海南分公司 | 一种3-奎宁环酮盐酸盐的检测方法及应用 |
| WO2021170772A1 (en) | 2020-02-26 | 2021-09-02 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling |
| WO2021180338A1 (en) | 2020-03-09 | 2021-09-16 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3775418A (en) * | 1970-07-15 | 1973-11-27 | American Home Prod | 3-((3-azaspiro(5,5)undecino)methyl)-3-quinuclidinol |
| EP1319000B1 (en) | 2000-09-20 | 2008-11-05 | Aprea Ab | Use of 1-azabicyclo 2.2.2 octan-3-one derivatives for treating cancer tumors |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| RU2226288C2 (ru) | 2001-07-10 | 2004-03-27 | ОПТИВА, Инк. | Многослойное оптическое покрытие |
| CA2476825C (en) * | 2002-02-21 | 2011-04-05 | Aprea Ab | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases |
| NZ542212A (en) | 2003-03-24 | 2008-04-30 | Aprea Ab | Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive WT P53 |
| SE0400708D0 (sv) * | 2004-03-22 | 2004-03-22 | Aprea Ab | New compounds and use thereof |
| JP2007269786A (ja) | 2006-03-09 | 2007-10-18 | Daiichi Sankyo Healthcare Co Ltd | パンテチン含有経口液剤 |
| JP2008001606A (ja) | 2006-06-20 | 2008-01-10 | Mitsubishi Pharma Corp | ピラゾロン化合物を含有する水溶液剤 |
| WO2008009756A1 (es) | 2006-07-18 | 2008-01-24 | Genfarma Laboratorio S.L. | Formulación líquida inyectable de paracetamol |
| JP2008201778A (ja) | 2007-01-25 | 2008-09-04 | Mochida Pharmaceut Co Ltd | バンコマイシン液状製剤 |
| PL2131845T3 (pl) | 2007-03-01 | 2012-09-28 | Novartis Ag | Metanosulfonian etyloamidu kwasu 5-(2,4-dihydroksy-5-izopropylo-fenylo)-4-(4-morfolin-4-ylometylofenylo)-izoksazolo-3-karboksylowego, jego hydraty i polimorfy, oraz preparaty zawierające te postacie |
| US9061016B2 (en) * | 2010-01-21 | 2015-06-23 | Aprea Ab | Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease |
-
2011
- 2011-01-21 US US13/521,841 patent/US9061016B2/en active Active
- 2011-01-21 PH PH1/2012/501402A patent/PH12012501402A1/en unknown
- 2011-01-21 BR BR112012017994A patent/BR112012017994B8/pt active IP Right Grant
- 2011-01-21 RU RU2012135698/15A patent/RU2571566C2/ru active
- 2011-01-21 DK DK11701392.0T patent/DK2525796T3/en active
- 2011-01-21 HU HUE11701392A patent/HUE028285T2/en unknown
- 2011-01-21 PT PT117013920T patent/PT2525796T/pt unknown
- 2011-01-21 JP JP2012549372A patent/JP5845193B2/ja active Active
- 2011-01-21 CN CN201610993086.1A patent/CN106963759B/zh active Active
- 2011-01-21 EP EP11701392.0A patent/EP2525796B1/en active Active
- 2011-01-21 SG SG2012052221A patent/SG182537A1/en unknown
- 2011-01-21 WO PCT/EP2011/050854 patent/WO2011089234A2/en not_active Ceased
- 2011-01-21 AU AU2011208681A patent/AU2011208681B2/en active Active
- 2011-01-21 CA CA2786824A patent/CA2786824C/en active Active
- 2011-01-21 CN CN201180006745.3A patent/CN102781447B/zh active Active
- 2011-01-21 ES ES11701392.0T patent/ES2578513T3/es active Active
- 2011-01-21 PL PL11701392.0T patent/PL2525796T3/pl unknown
- 2011-01-21 KR KR1020127021595A patent/KR101727085B1/ko active Active
- 2011-01-21 IN IN5192DEN2012 patent/IN2012DN05192A/en unknown
-
2012
- 2012-06-12 IL IL220318A patent/IL220318A/en active IP Right Grant
- 2012-06-15 ZA ZA2012/04424A patent/ZA201204424B/en unknown
-
2015
- 2015-08-05 JP JP2015154860A patent/JP6106228B2/ja active Active
-
2016
- 2016-06-17 CY CY20161100546T patent/CY1117659T1/el unknown
- 2016-06-20 SM SM201600189T patent/SMT201600189B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012501402A1 (en) | Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease | |
| EA201290078A1 (ru) | Гетероциклические соединения для ингибирования pask | |
| NZ609309A (en) | Redox drug derivatives | |
| PH12016500225A1 (en) | Novel quinoline-substituted compound | |
| NZ626618A (en) | Hydroxamic acid derivatives and uses thereof | |
| MY164731A (en) | Compound | |
| IN2012DN01453A (enExample) | ||
| EA201200952A1 (ru) | Производные пиразина и их применение для лечения неврологических нарушений | |
| EA201490493A1 (ru) | Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы | |
| EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
| EA201390826A1 (ru) | ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA | |
| MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. | |
| EP4327886A3 (en) | Pyrimido- pyridazinone compounds and use thereof | |
| MX2011009493A (es) | Compuestos para el tratamiento de trastornos metabolicos. | |
| GEP20196969B (en) | New therapeutical composition containing apomorphine as active ingredient | |
| MX342947B (es) | Tratamiento de diabetes tipo 2. | |
| MX2009007265A (es) | Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion. | |
| MX2014005895A (es) | Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis. | |
| IN2012DN00953A (enExample) | ||
| IN2011KN05169A (enExample) | ||
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| EA201001405A1 (ru) | Стимуляторы секреции инсулина - производные пиридопиразинонов, способы их получения и их применение для лечения диабета | |
| MX336477B (es) | Derivado de aminoacido. | |
| MX2015007862A (es) | Derivado de amida del acido cinamico. | |
| MX354846B (es) | Metodos para tratar gota en sub-poblaciones de pacientes. |